James W Freeman
Overview
Explore the profile of James W Freeman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
1196
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chen C, Zhao S, Zhao X, Cao L, Karnad A, Kumar A, et al.
Cell Death Dis
. 2022 Aug;
13(8):682.
PMID: 35931675
Chemoresistance in pancreatic cancer cells may be caused by the expansion of inherently resistant cancer cells or by the adaptive plasticity of initially sensitive cancer cells. We investigated how CD44...
2.
Chen C, Zhao S, Karnad A, Freeman J
J Hematol Oncol
. 2018 May;
11(1):64.
PMID: 29747682
CD44, a non-kinase transmembrane glycoprotein, is overexpressed in several cell types including cancer stem cells and frequently shows alternative spliced variants that are thought to play a role in cancer...
3.
Zhao S, Chen C, Chang K, Karnad A, Jagirdar J, Kumar A, et al.
Clin Cancer Res
. 2016 Jun;
22(22):5592-5604.
PMID: 27267855
Purpose: A subpopulation of pancreatic ductal adenocarcinoma (PDAC) cells is thought to be inherently resistant to chemotherapy or to give rise to tumor cells that become resistant during treatment. Here...
4.
Gong J, Munoz A, Pingali S, Payton-Stewart F, Chan D, Freeman J, et al.
Mol Carcinog
. 2016 May;
56(2):402-411.
PMID: 27208550
There is an unmet need to develop new agents or strategies against therapy resistant pancreatic cancer (PanCA). Recent studies from our laboratory showed that STAT3 negatively regulates NF-κB and that...
5.
Chang K, Karnad A, Zhao S, Freeman J
Oncotarget
. 2015 Mar;
6(6):3507-18.
PMID: 25784650
c-Met and receptor originated from nantes (RON) are structurally related transmembrane phosphotyrosine kinase receptors. c-Met and RON show increased expression or activity in a variety of tumors leading to tumor...
6.
Bera A, VenkataSubbaRao K, Manoharan M, Hill P, Freeman J
PLoS One
. 2014 Sep;
9(9):e106343.
PMID: 25184537
In this study a microRNA (miRNA) signature was identified in a gemcitabine resistant pancreatic ductal adenocarcinoma (PDAC) cell line model (BxPC3-GZR) and this signature was further examined in advanced PDAC...
7.
Chang Z, Ju H, Ling J, Zhuang Z, Li Z, Wang H, et al.
PLoS One
. 2014 Jul;
9(7):e101452.
PMID: 25029561
Activation of K-ras and inactivation of p16 are the most frequently identified genetic alterations in human pancreatic epithelial adenocarcinoma (PDAC). Mouse models engineered with mutant K-ras and deleted p16 recapitulate...
8.
Gong J, Xie J, Bedolla R, Rivas P, Chakravarthy D, Freeman J, et al.
Clin Cancer Res
. 2014 Feb;
20(5):1259-73.
PMID: 24520096
Purpose: Near equal rates of incidence and mortality emphasize the need for novel targeted approaches for better management of patients with pancreatic cancer. Inflammatory molecules NF-κB and STAT3 are overexpressed...
9.
Bera A, Zhao S, Cao L, Chiao P, Freeman J
PLoS One
. 2013 Dec;
8(12):e82282.
PMID: 24340014
Activating K-Ras mutations and inactivating mutations of Smad4 are two common genetic alterations that occur in the development and progression of pancreatic ductal adenocarcinomas (PDAC). To further study the individual...
10.
VenkataSubbaRao K, Peterson L, Zhao S, Hill P, Cao L, Zhou Q, et al.
Mol Cancer
. 2013 Sep;
12(1):104.
PMID: 24025152
Background: Among the solid tumors, human pancreatic ductal adenocarcinoma (PDAC) has the worst prognosis. Gemcitabine is the standard first line of therapy for pancreatic cancer but has limited efficacy due...